Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as C$2.62 and last traded at C$2.46, with a volume of 666739 shares traded. The stock had previously closed at C$1.95.
Medicenna Therapeutics Trading Up 27.7 %
The company has a market cap of C$173.40 million, a P/E ratio of -10.83 and a beta of 1.16. The stock’s 50 day moving average is C$1.54 and its 200-day moving average is C$0.83. The company has a current ratio of 5.00, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- What is the Euro STOXX 50 Index?
- MarketBeat Week in Review – 4/22 – 4/26
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are Dividend Challengers?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
